Could a common diabetes drug stop oral cancer before it starts?
NCT ID NCT02581137
First seen Mar 09, 2026 · Last updated May 17, 2026 · Updated 10 times
Summary
This study tests whether metformin, a drug used for diabetes, can prevent oral cancer in people with precancerous mouth lesions (leukoplakia or erythroplakia). About 26 participants took metformin to see if their lesions shrank or disappeared. The goal is to find a simple way to stop these lesions from turning into cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ERYTHROPLAKIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
BC Cancer Research Centre
Vancouver, British Columbia, V5Z 1L3, Canada
-
UC San Diego Medical Center - Hillcrest
San Diego, California, 92103, United States
-
University of British Columbia Hospital
Vancouver, British Columbia, V6T 2B5, Canada
-
University of Minnesota/Masonic Cancer Center
Minneapolis, Minnesota, 55455, United States
Conditions
Explore the condition pages connected to this study.